Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials

被引：0
|
作者：
Herbel, N. [1 ]
Ouali, K. [1 ]
Danlos, F-X. [1 ]
Massard, C. P. [1 ]
Goldschmidt, V. [1 ]
Michot, J-M. [1 ]
Laparra, A. [2 ]
Bernard-Tessier, A. [3 ]
Gazzah, A. [1 ]
Bahleda, R. [1 ]
Hollebecque, A. [1 ]
Henon, C. [1 ]
Postel-Vinay, S. [1 ]
Loriot, Y. [1 ]
Ribrag, V. [1 ]
Marabelle, A. [1 ]
Fizazi, K. [3 ]
Aix, S. Ponce [1 ]
Champiat, S. [1 ]
Baldini, C. [1 ]
机构：
[1] Inst Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Inst Gustave Roussy, DIOPP, Villejuif, France
[3] Gustave Roussy Canc Campus, Med Oncol Dept, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
657P
引用
收藏
页码：S519 / S519
页数：1
相关论文
共 50 条
  • [11] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [12] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [13] CD123-CODV-TCE bispecific T-cell engager for acute myeloid leukemia (AML): Activity on primary AML and safety in non-human primates
    Bonnevaux, Helene
    Courta, Jacqueline
    Passe-Coutrin, Wilfried
    Bauchet, Anne-Laure
    Roobrouck, Annelies
    Amara, Celine
    Beys, Eric
    Balzano, Marielle
    Moulard, Maxime
    Meloni, Marco
    Dullaers, Melissa
    Chiron, Marielle
    Virone-Oddos, Angela
    CANCER RESEARCH, 2022, 82 (12)
  • [14] Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
    Wermke, Martin
    Felip, Enriqueta
    Gambardella, Valentina
    Kuboki, Yasutoshi
    Morgensztern, Daniel
    Hamed, Zohra Oum'
    Liu, Meiruo
    Studeny, Matus
    Owonikoko, Taofeek K.
    FUTURE ONCOLOGY, 2022, 18 (24) : 2639 - 2649
  • [15] A bispecific T-cell engager antibody (BiTE) against TAG-72/CD3 for targeted cancer immunotherapy
    Khambati, Fatema
    Soliman, Hatem
    CANCER RESEARCH, 2019, 79 (13)
  • [16] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
    Cugnetti, Ana Paula
    Liu, Haizhen
    McNeeley, Patricia
    Wheeler, Christina
    Lucas, Matthew
    Xing, Charles
    Joyner, Solmarie
    Johnson, Kyrie
    Woodard, Kathryn
    Zhou, Wei
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2023, 83 (07)
  • [17] A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
    Mau-Sorensen, Morten
    Dittrich, Christian
    Dienstmann, Rodrigo
    Lassen, Ulrik
    Buechler, Wilfried
    Martinius, Holger
    Tabernero, Josep
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 1065 - 1073
  • [18] A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
    Morten Mau-Sørensen
    Christian Dittrich
    Rodrigo Dienstmann
    Ulrik Lassen
    Wilfried Büchler
    Holger Martinius
    Josep Tabernero
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1065 - 1073
  • [19] Melanoma cells can be eliminated by sialylated CD43 x CD3 bispecific T cell engager formats in vitro and in vivo
    de Jong, G.
    Bartels, L.
    Kedde, M.
    Verdegaal, E. M. E.
    Gillissen, M. A.
    Levie, S. E.
    Cercel, M. G.
    van Hal-van Veen, S. E.
    Fatmawati, C.
    van de Berg, D.
    Yasuda, E.
    Claassen, Y. B.
    Bakker, A. Q.
    van der Burg, S. H.
    Schotte, R.
    Villaudy, J.
    Spits, H.
    Hazenberg, M. D.
    van Helden, P. M.
    Wagner, K.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (06) : 1569 - 1581
  • [20] A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)
    Zabaleta, Aintzane
    Martin-Sanchez, Esperanza
    Blanco, Laura
    Kim, Peter
    Bisht, Kamlesh
    Wang, Hongfang
    Van de Velde, Helgi J.
    Jelinek, Tomas
    Simoes, Catia
    Prosper, Felipe
    San-Miguel, Jesus
    Martinez-Cuadron, David
    Montesinos, Pau
    Paiva, Bruno
    BLOOD, 2023, 142
12345